COVID-19 patients with Gilead's antiviral drug, remdesivir, after the healthcare regulator's endorsement put it on track to become the first therapy for the disease on the continent.The European Medicines Agency (EMA) said on Thursday that its human medicines committee (CHMP) recommended conditionally approving the drug for adults and adolescents from 12 years of age who are also suffering from pneumonia and require oxygen support.European Union conditional marketing authorisation allows a treatment to be sold for a year in the 27-nation bloc, before all necessary data on its efficacy and side-effects are available.